Boiron SA
Boiron SA, a leading name in the homeopathic industry, is headquartered in France and operates extensively across Europe and beyond. Founded in 1932, the company has established itself as a pioneer in the development and distribution of homeopathic medicines, focusing on natural remedies that cater to a variety of health needs. Boiron's core product offerings include a wide range of homeopathic treatments, such as pellets, ointments, and syrups, which are distinguished by their commitment to quality and efficacy. The company is renowned for its innovative approach to homeopathy, utilising rigorous scientific methods to ensure the highest standards. With a strong market position, Boiron SA has achieved notable milestones, including international expansion and recognition as a trusted brand among healthcare professionals and consumers alike. Its dedication to promoting natural health solutions continues to set it apart in the competitive landscape of the pharmaceutical industry.
DitchCarbon Score
How does Boiron SA's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Boiron SA's score of 30 is higher than 54% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Boiron SA's reported carbon emissions
In 2023, Boiron SA reported total carbon emissions of approximately 63,000,000 kg CO2e, with 2,400,000 kg CO2e attributed to Scope 1 emissions and the remaining 61,700,000 kg CO2e classified as Scope 3 emissions. This data indicates a consistent emission profile, as the figures for Scope 1 and Scope 3 emissions remained unchanged from 2022. Despite the significant emissions, Boiron has not disclosed any specific reduction targets or initiatives aimed at decreasing their carbon footprint. The absence of documented climate pledges or science-based targets suggests that while the company is aware of its emissions, it has yet to commit to formal reduction strategies. As a leader in the pharmaceutical industry, Boiron's climate commitments and emissions management will be crucial in aligning with global sustainability goals and addressing the increasing scrutiny on corporate environmental impact.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 2,400,000 | 0,000,000 |
| Scope 2 | - | - |
| Scope 3 | 61,700,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Boiron SA is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
